Michael Koren, MD
Cardiovascular Disease · Gainesville, FLNPI 1083645782
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,092 of the $97,034 with a category attached, or 70.2%. 36 manufacturers reported payments, led by Novartis at 33.7% of the total. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $480.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$33K
- Astrazeneca UK Limited$18K
- AstraZeneca$12K
- Sanofi-aventis U.S. LLC$11K
- Idorsia Pharmaceuticals US Inc$10K
- Astrazeneca AB$4K
- plus $8K from 30 others
Across 1,880 payments — averaging $16,479 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$15.5M
- Astrazeneca UK Limited$4.4M
- Pfizer$2.5M
- Novartis$2M
- AstraZeneca$1.8M
- Amgen$1.5M
- plus $3.2M from 15 others
What the payments were for
- Consulting fees$68,09270%
- Speaking & faculty fees$17,14218%
- Travel & lodging$6,2536%
- Food & beverage$5,5056%
- Education$230%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $32,735 |
| Astrazeneca UK Limited | 27 | $17,733 |
| AstraZeneca | 8 | $12,278 |
| Sanofi-aventis U.S. LLC | 13 | $11,224 |
| Idorsia Pharmaceuticals US Inc | 3 | $10,345 |
| Astrazeneca AB | 3 | $4,423 |
| Novo Nordisk | 8 | $3,066 |
| Modernatx, Inc. | 15 | $2,614 |
| Merck | 10 | $446 |
| Amgen | 10 | $318 |
| Sanofi | 3 | $225 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $183 |
| Medtronic | 4 | $165 |
| Boehringer Ingelheim | 7 | $154 |
| Actelion Pharmaceuticals US, Inc. | 5 | $133 |
| Siemens Medical Solutions USA, Inc. | 1 | $118 |
| Pfizer | 6 | $108 |
| Cvrx, Inc. | 3 | $89 |
| Johnson & Johnson | 7 | $88 |
| Amarin Pharma, Inc. | 4 | $74 |
| Boston Scientific | 3 | $65 |
| Lexicon Pharmaceuticals, Inc. | 1 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Biotronik Inc. | 2 | $43 |
| Philips North America LLC | 2 | $41 |
| Abbott | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Teleflex LLC | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| GE HealthCare | 1 | $15 |
| Bayer | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
| Elutia, Inc. | 1 | $12 |
| Venclose Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,034 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $159,463 |
| EntrestoSacubitril/Valsartan | 26 | $42,002 |
| XareltoRivaroxaban | 23 | $20,156 |
| Repatha SyringeEvolocumab | 22 | $19,913 |
| OzempicSemaglutide | 19 | $19,741 |
| FarxigaDapagliflozin Propanediol | 24 | $19,366 |
| Repatha SureclickEvolocumab | 16 | $17,450 |
| BrilintaTicagrelor | 25 | $13,305 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 73 | $3,217 |
| Metoprolol Succinate | 180 | $2,898 |
| Dofetilide | 30 | $2,897 |
| Atorvastatin Calcium | 319 | $2,745 |
| Potassium Chloride | 114 | $2,312 |
| Rosuvastatin Calcium | 130 | $2,037 |
| Carvedilol | 173 | $1,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $108 | $159,463145 claims |
| NovartisEntresto | $32,735 | $42,00226 claims |
| AstraZenecaFarxiga, Brilinta | $12,278 | $32,67149 claims |
| Johnson & JohnsonXarelto | $88 | $20,15623 claims |
| Novo NordiskOzempic | $3,066 | $19,74119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Gainesville
- Juan ArandaGainesville$212K
- Keith MarchGainesville$176K
- Ann TongGainesville$160K
- Carlos Alviar RestrepoGainesville$104K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.